scholarly journals The Effect of Rebamipide on Ocular Surface Disorders Induced by Latanoprost and Timolol in Glaucoma Patients

2015 ◽  
Vol 2015 ◽  
pp. 1-5 ◽  
Author(s):  
Naoto Tokuda ◽  
Yasushi Kitaoka ◽  
Akiko Matsuzawa ◽  
Junsuke Miyamoto ◽  
Shinsuke Sakae ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Ocular Surface ◽  
Barrier Function ◽  
Epithelial Barrier ◽  
Control Group ◽  
Eye Drops ◽  
Drug Induced ◽  
Epithelial Barrier Function ◽  
Corneal Epithelial ◽  
Significant Difference

Purpose. To examine the efficacy of ophthalmic rebamipide suspensions on ocular surface disorders induced by antiglaucoma eye drops.Patients and Methods. Forty eyes of 40 patients receiving latanoprost (0.005%) and timolol (0.5%) were included in this randomized prospective study. The patients were randomly divided into two groups (n= 20): the rebamipide-treated group and control group. Changes in intraocular pressure, tear film break-up time (TBUT), and corneal epithelial barrier function were evaluated at baseline, 4 weeks, and 8 weeks after rebamipide administration. Furthermore, superficial punctate keratopathy severity was evaluated by scoring the lesion area and density.Results. There was no significant difference in intraocular pressure before and after rebamipide treatment. However, corneal epithelial barrier function improved significantly 4 and 8 weeks after rebamipide treatment. TBUT was partially, but significantly, increased (P= 0.02) 8 weeks after rebamipide treatment, whereas no significant change was observed at 4 weeks. Additionally, a significant decrease in area and density of keratopathy was observed 8 weeks after rebamipide treatment but not at 4 weeks. The control group showed no significant difference compared to baseline.Conclusions. Our data suggests that rebamipide treatment may reduce the occurrence of drug-induced ocular surface disorder.

scholarly journals Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost

2017 ◽  
Vol 2017 ◽  
pp. 1-6 ◽  
Author(s):  
Naoto Tokuda ◽  
Yasushi Kitaoka ◽  
Akiko Matsuzawa ◽  
Ayaka Tsukamoto ◽  
Kana Sase ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Barrier Function ◽  
Benzalkonium Chloride ◽  
Tear Film ◽  
Ophthalmic Solution ◽  
Surface Characteristics ◽  
Epithelial Barrier ◽  
Epithelial Barrier Function ◽  
Corneal Epithelial ◽  
Preservative Free

Purpose. The aim of the present study was to examine the effects of switching from Latanoprost ophthalmic solution containing a preservative to preservative-free Tafluprost ophthalmic solution or Tafluprost containing a preservative on ocular surfaces. Materials and Methods. Forty patients (40 eyes) with glaucoma (mean age: 62.0 ± 10.9 years) using Latanoprost with preservative for six months or longer were assigned either to a Tafluprost-containing-preservative group (20 eyes) or preservative-free-Tafluprost group (20 eyes). The intraocular pressure, corneal epithelial barrier function (fluorescein uptake concentration with fluorophotometer FL-500), superficial punctate keratopathy (AD classification), and tear film breakup time (TBUT) were assessed before switching and at 12 weeks after switching. Results. No significant differences in intraocular pressure were noted after switching in either group. Corneal epithelial barrier function was improved significantly after switching in both the Tafluprost-containing-preservative and the preservative-free-Tafluprost groups. There were no significant differences in AD scores after switching in the Tafluprost-containing-preservative group, but significant improvements were noted in the preservative-free-Tafluprost group. No significant differences in TBUT were noted in the Tafluprost-containing-preservative or preservative-free-Tafluprost groups after switching. Conclusion. After switching from preservative Latanoprost to Tafluprost containing-preservative or preservative-free Tafluprost, corneal epithelial barrier function was improved while the intraocular pressure reduction was retained.

Effect of Beta-Blocker Eyedrops on Corneal Epithelial Barrier Function

2000 ◽  
Vol 214 (5) ◽  
pp. 332-336 ◽  
Author(s):  
Akiko Niiya ◽  
Norihiko Yokoi ◽  
Yasuhiro Matsumoto ◽  
Aoi Komuro ◽  
Takeshi Ishibashi ◽  
...  
Keyword(s):  
Beta Blocker ◽  
Barrier Function ◽  
Epithelial Barrier ◽  
Epithelial Barrier Function ◽  
Corneal Epithelial

scholarly journals Investigation of the Relation Between Epithelial Barrier Function and Autism Symptom Severity in Children with Autism Spectrum Disorder

2021 ◽  
Author(s):  
Kevser Nalbant ◽  
Semih Erden ◽  
Abdullah Yazar ◽  
İbrahim Kılınç
Keyword(s):  
Autism Spectrum Disorder ◽  
Barrier Function ◽  
Rating Scale ◽  
Autism Spectrum ◽  
Spectrum Disorder ◽  
Enzyme Linked Immunosorbent Assay ◽  
Epithelial Barrier ◽  
Control Group ◽  
Epithelial Barrier Function ◽  
Children With Asd

Abstract Autism spectrum disorder (ASD) is a common neurodevelopmental disorder characterized by limitations in mutual communication and social interaction as well as restricted, repetitive patterns of behaviors, interests, or activities. A number of biological abnormalities have been reported in ASD. Therefore the possible role of biological abnormalities in etiopathogenesis arouses research interest in this area. This is a case-control design study evaluating epithelial barrier function by comparing serum concentrations of occludin and zonulin in children with ASD (n = 60) and controls (n = 30). The Childhood Autism Rating Scale (CARS) was used to evaluate autistic symptom levels of all children. Serum occludin and zonulin levels were analyzed using an enzyme-linked immunosorbent assay. Serum occludin was significantly lower in children with ASD than in control subjects. In children with ASD, a decrease in occludin level was significantly associated with the disorder symptom levels item mean score (CARS total scores). Our findings showed that children with ASD had alterations in epithelial barrier function compared to the control group. The investigation of the mechanism underlying the different levels of occludin between ASD and controls may be of importance in clarifying the etiopathogenesis of ASD, as well as its follow-up and treatment.

Prospective study comparing Xalatan® eye drops and two similar generics as to the efficacy and safety profile

2018 ◽  
Vol 28 (4) ◽  
pp. 378-384 ◽  
Author(s):  
Andreas Diagourtas ◽  
Kostantinos Kagelaris ◽  
Kostantinos Oikonomakis ◽  
Andreas Droulias ◽  
Nikolaos Kokolakis ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Safety Profile ◽  
Ocular Surface ◽  
Disease Index ◽  
Ocular Surface Disease ◽  
Eye Drops ◽  
Efficacy And Safety ◽  
Ocular Surface Disease Index ◽  
Significant Difference ◽  
The Mean

Purpose: To evaluate the efficacy and safety between two generic prostaglandins Lataz–Xalaprost (Greece) and the corresponding original drops (Xalatan®). Material and methods: In this prospective randomized study, 60 patients diagnosed with open-angle glaucoma or ocular hypertension were enrolled, who had never received antiglaucoma treatment. Subjects were divided randomly into three groups (Xalatan, Lataz, and Xalaprost groups) and they were studied over 16 weeks. At each visit, the mean applanation tonometry values and tear break-up time were measured. The Ocular Surface Disease Index questionnaire was used to evaluate patient’s symptoms. Results: There was a statistically significant difference (p < 0.001) in the mean values of the intraocular pressure between the baseline and the last visit (Xalatan group: from 23.11 ± 1.61 mmHg to 15.81 ± 1.22 mmHg, Lataz group: from 23.26 ± 1.33 mmHg to 15.80 ± 1.47 mmHg, and Xalaprost group: from 23.08 ± 1.45 mmHg to 16.08 ± 1.38 mmHg). Both generic eye drops showed mean percentage intraocular pressure reduction comparable to the standards of prostaglandin analogues (Xalatan: 31.57%, Lataz: 32.06%, and Xalaprost: 30.34%). Xalatan reduced the tear break-up time less, followed by Lataz and then by Xalaprost (Xalatan: from 8.5 to 8 s, Lataz: from 8.2 to 7.4 s, and Xalaprost: from 8.7 to 7.7 s). Xalatan presented the best safety profile, followed by Lataz and least was Xalaprost, according to Ocular Surface Disease Index questionnaire’s results. Conclusion: No significant difference was recorded in the effectiveness of each generic prostaglandin compared to the original. Furthermore, no patient had to change medication. The differences that arose in the safety profile of the three eye drops suggest a prompt closer initial monitoring of patients who are administered generic eye drops.

scholarly journals P 154 Effects of contact lens use to corneal epithelial barrier function by objective fluorophotometer

1995 ◽  
Vol 35 ◽  
pp. S180
Author(s):  
T. Takahashi ◽  
Y. Enomoto ◽  
M. Itoi ◽  
N. Itoh ◽  
K. Nakayasu ◽  
...  
Keyword(s):  
Contact Lens ◽  
Barrier Function ◽  
Epithelial Barrier ◽  
Epithelial Barrier Function ◽  
Corneal Epithelial

Impairment of corneal epithelial barrier function in diabetics

1989 ◽  
Vol 227 (2) ◽  
pp. 142-144 ◽  
Author(s):  
Martin Göbbels ◽  
Manfred Spitznas ◽  
Joachim Oldendoerp
Keyword(s):  
Barrier Function ◽  
Epithelial Barrier ◽  
Epithelial Barrier Function ◽  
Corneal Epithelial
Sign in / Sign up

Export Citation Format

Share Document